Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
Provided By GlobeNewswire
Last update: Apr 8, 2025
Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed or refractory B-cell lymphomas.
Read more at globenewswire.com5.41
-0.09 (-1.64%)
Find more stocks in the Stock Screener
RXRX Latest News and Analysis
11 days ago - ChartmillThe market is filled with gapping stocks in Friday's session.The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
12 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
